Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2014-07-22

AUTHORS

Dipen A Patel, Andrew F Shorr, Jean Chastre, Michael Niederman, Andrew Simor, Jennifer M Stephens, Claudie Charbonneau, Xin Gao, Dilip Nathwani

ABSTRACT

IntroductionWe compared the economic impacts of linezolid and vancomycin for the treatment of hospitalized patients with methicillin-resistant Staphylococcus aureus (MRSA)–confirmed nosocomial pneumonia.MethodsWe used a 4-week decision tree model incorporating published data and expert opinion on clinical parameters, resource use and costs (in 2012 US dollars), such as efficacy, mortality, serious adverse events, treatment duration and length of hospital stay. The results presented are from a US payer perspective. The base case first-line treatment duration for patients with MRSA-confirmed nosocomial pneumonia was 10 days. Clinical treatment success (used for the cost-effectiveness ratio) and failure due to lack of efficacy, serious adverse events or mortality were possible clinical outcomes that could impact costs. Cost of treatment and incremental cost-effectiveness per successfully treated patient were calculated for linezolid versus vancomycin. Univariate (one-way) and probabilistic sensitivity analyses were conducted.ResultsThe model allowed us to calculate the total base case inpatient costs as $46,168 (linezolid) and $46,992 (vancomycin). The incremental cost-effectiveness ratio favored linezolid (versus vancomycin), with lower costs ($824 less) and greater efficacy (+2.7% absolute difference in the proportion of patients successfully treated for MRSA nosocomial pneumonia). Approximately 80% of the total treatment costs were attributed to hospital stay (primarily in the intensive care unit). The results of our probabilistic sensitivity analysis indicated that linezolid is the cost-effective alternative under varying willingness to pay thresholds.ConclusionThese model results show that linezolid has a favorable incremental cost-effectiveness ratio compared to vancomycin for MRSA-confirmed nosocomial pneumonia, largely attributable to the higher clinical trial response rate of patients treated with linezolid. The higher drug acquisition cost of linezolid was offset by lower treatment failure–related costs and fewer days of hospitalization. More... »

PAGES

r157

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/cc13996

DOI

http://dx.doi.org/10.1186/cc13996

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1039630305

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/25053453


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Acetamides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Bacterial Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cross Infection", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Linezolid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Methicillin-Resistant Staphylococcus aureus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Models, Economic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oxazolidinones", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pneumonia, Staphylococcal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vancomycin", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Pharmerit International, 4350 East West Highway, Suite 430, 20814, Bethesda, MD, USA", 
          "id": "http://www.grid.ac/institutes/grid.482835.0", 
          "name": [
            "Pharmerit International, 4350 East West Highway, Suite 430, 20814, Bethesda, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Patel", 
        "givenName": "Dipen A", 
        "id": "sg:person.01365552716.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01365552716.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pulmonary & Critical Care Medicine, Washington Hospital Center, 110 Irving St NW, 20010, Washington, DC, USA", 
          "id": "http://www.grid.ac/institutes/grid.415235.4", 
          "name": [
            "Department of Pulmonary & Critical Care Medicine, Washington Hospital Center, 110 Irving St NW, 20010, Washington, DC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shorr", 
        "givenName": "Andrew F", 
        "id": "sg:person.0606505446.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0606505446.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Service de R\u00e9animation M\u00e9dicale Institut de Cardiologie Groupe, Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, 47-83 boulevard de l'H\u00f4pital, 75651, Paris Cedex 13, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Service de R\u00e9animation M\u00e9dicale Institut de Cardiologie Groupe, Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, 47-83 boulevard de l'H\u00f4pital, 75651, Paris Cedex 13, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chastre", 
        "givenName": "Jean", 
        "id": "sg:person.0714077601.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0714077601.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Winthrop-University Hospital, 222 Station Plaza N, Suite 509, 11501, Mineola, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.281603.e", 
          "name": [
            "Department of Medicine, Winthrop-University Hospital, 222 Station Plaza N, Suite 509, 11501, Mineola, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Niederman", 
        "givenName": "Michael", 
        "id": "sg:person.01305416464.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01305416464.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Microbiology, Sunnybrook Health Sciences Centre, B121-2075 Bayview Ave., M4N 3M5, Toronto, ON, Canada", 
          "id": "http://www.grid.ac/institutes/grid.413104.3", 
          "name": [
            "Department of Microbiology, Sunnybrook Health Sciences Centre, B121-2075 Bayview Ave., M4N 3M5, Toronto, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Simor", 
        "givenName": "Andrew", 
        "id": "sg:person.0664111222.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0664111222.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pharmerit International, 4350 East West Highway, Suite 430, 20814, Bethesda, MD, USA", 
          "id": "http://www.grid.ac/institutes/grid.482835.0", 
          "name": [
            "Pharmerit International, 4350 East West Highway, Suite 430, 20814, Bethesda, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stephens", 
        "givenName": "Jennifer M", 
        "id": "sg:person.015004431252.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015004431252.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Outcomes Research-Europe Infectious Diseases, Pfizer International Operations Specialty, Business Unit 23-25, avenue du Dr Lannelongue, F-75668, Paris Cedex 14, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Outcomes Research-Europe Infectious Diseases, Pfizer International Operations Specialty, Business Unit 23-25, avenue du Dr Lannelongue, F-75668, Paris Cedex 14, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Charbonneau", 
        "givenName": "Claudie", 
        "id": "sg:person.01340540240.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340540240.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pharmerit International, 4350 East West Highway, Suite 430, 20814, Bethesda, MD, USA", 
          "id": "http://www.grid.ac/institutes/grid.482835.0", 
          "name": [
            "Pharmerit International, 4350 East West Highway, Suite 430, 20814, Bethesda, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gao", 
        "givenName": "Xin", 
        "id": "sg:person.01103526344.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01103526344.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ninewells Hospital & Medical School, Ward 42, East Block, DD19SY, Dundee, UK", 
          "id": "http://www.grid.ac/institutes/grid.416266.1", 
          "name": [
            "Ninewells Hospital & Medical School, Ward 42, East Block, DD19SY, Dundee, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nathwani", 
        "givenName": "Dilip", 
        "id": "sg:person.01104424502.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01104424502.36"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s15010-008-8046-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012222331", 
          "https://doi.org/10.1007/s15010-008-8046-7"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-07-22", 
    "datePublishedReg": "2014-07-22", 
    "description": "IntroductionWe compared the economic impacts of linezolid and vancomycin for the treatment of hospitalized patients with methicillin-resistant Staphylococcus aureus (MRSA)\u2013confirmed nosocomial pneumonia.MethodsWe used a 4-week decision tree model incorporating published data and expert opinion on clinical parameters, resource use and costs (in 2012 US dollars), such as efficacy, mortality, serious adverse events, treatment duration and length of hospital stay. The results presented are from a US payer perspective. The base case first-line treatment duration for patients with MRSA-confirmed nosocomial pneumonia was 10\u00a0days. Clinical treatment success (used for the cost-effectiveness ratio) and failure due to lack of efficacy, serious adverse events or mortality were possible clinical outcomes that could impact costs. Cost of treatment and incremental cost-effectiveness per successfully treated patient were calculated for linezolid versus vancomycin. Univariate (one-way) and probabilistic sensitivity analyses were conducted.ResultsThe model allowed us to calculate the total base case inpatient costs as $46,168 (linezolid) and $46,992 (vancomycin). The incremental cost-effectiveness ratio favored linezolid (versus vancomycin), with lower costs ($824 less) and greater efficacy (+2.7% absolute difference in the proportion of patients successfully treated for MRSA nosocomial pneumonia). Approximately 80% of the total treatment costs were attributed to hospital stay (primarily in the intensive care unit). The results of our probabilistic sensitivity analysis indicated that linezolid is the cost-effective alternative under varying willingness to pay thresholds.ConclusionThese model results show that linezolid has a favorable incremental cost-effectiveness ratio compared to vancomycin for MRSA-confirmed nosocomial pneumonia, largely attributable to the higher clinical trial response rate of patients treated with linezolid. The higher drug acquisition cost of linezolid was offset by lower treatment failure\u2013related costs and fewer days of hospitalization.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/cc13996", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1117766", 
        "issn": [
          "1364-8535", 
          "1466-609X"
        ], 
        "name": "Critical Care", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "18"
      }
    ], 
    "keywords": [
      "incremental cost-effectiveness ratio", 
      "serious adverse events", 
      "methicillin-resistant Staphylococcus aureus", 
      "nosocomial pneumonia", 
      "cost-effectiveness ratio", 
      "probabilistic sensitivity analyses", 
      "hospital stay", 
      "adverse events", 
      "treatment duration", 
      "higher drug acquisition costs", 
      "favourable incremental cost-effectiveness ratio", 
      "days of hospitalization", 
      "US payer perspective", 
      "drug acquisition costs", 
      "lack of efficacy", 
      "clinical treatment success", 
      "trial response rates", 
      "possible clinical outcomes", 
      "total treatment costs", 
      "Staphylococcus aureus", 
      "cost of treatment", 
      "clinical outcomes", 
      "clinical parameters", 
      "inpatient costs", 
      "treatment success", 
      "payer perspective", 
      "response rate", 
      "linezolid", 
      "pneumonia", 
      "patients", 
      "greater efficacy", 
      "vancomycin", 
      "treatment costs", 
      "efficacy", 
      "stay", 
      "mortality", 
      "MRSA", 
      "ResultsThe model", 
      "expert opinion", 
      "treatment", 
      "acquisition costs", 
      "duration", 
      "aureus", 
      "days", 
      "decision tree model", 
      "cost-effective alternative", 
      "hospitalization", 
      "IntroductionWe", 
      "economic impact", 
      "resource use", 
      "MethodsWe", 
      "univariate", 
      "outcomes", 
      "sensitivity analysis", 
      "events", 
      "failure", 
      "results", 
      "ratio", 
      "impact", 
      "rate", 
      "lack", 
      "analysis", 
      "use", 
      "threshold", 
      "data", 
      "willingness", 
      "tree model", 
      "success", 
      "alternative", 
      "opinion", 
      "cost", 
      "length", 
      "model", 
      "perspective", 
      "low cost", 
      "parameters", 
      "model results"
    ], 
    "name": "Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus", 
    "pagination": "r157", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1039630305"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/cc13996"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "25053453"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/cc13996", 
      "https://app.dimensions.ai/details/publication/pub.1039630305"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:57", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_640.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/cc13996"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/cc13996'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/cc13996'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/cc13996'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/cc13996'


 

This table displays all metadata directly associated to this object as RDF triples.

267 TRIPLES      21 PREDICATES      116 URIs      107 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/cc13996 schema:about N0f1e1e1459c74b549414e0883fef3810
2 N1909b9317ede46c388c4868e7a9ccfb8
3 N23bf28b77f5e4c6eabca42d37d48224a
4 N23c5d2311cf9422db8bb12ccc17efc17
5 N2bf221c08e244e9e935e76f74141840d
6 N4d87ec0f960441deb0d631ed3741515f
7 N5fefa93e614943ab980e106676243e78
8 N934ea1cd959e4a40a05775c60179f4bd
9 N9b6bc379ab8b4d8eb6e5890d286a438a
10 N9e708ebc23fd4c86a5ad49098d958412
11 Na7b09744ce5d4a709fee06e9967d9d01
12 Ndcb717e2bca3467ab8d49e31ae0179ac
13 Nff1d084527a64747bb8b05e7e32ee5ac
14 anzsrc-for:11
15 anzsrc-for:1103
16 schema:author N48874feec3dc439081ed94bc6079a05a
17 schema:citation sg:pub.10.1007/s15010-008-8046-7
18 schema:datePublished 2014-07-22
19 schema:datePublishedReg 2014-07-22
20 schema:description IntroductionWe compared the economic impacts of linezolid and vancomycin for the treatment of hospitalized patients with methicillin-resistant Staphylococcus aureus (MRSA)–confirmed nosocomial pneumonia.MethodsWe used a 4-week decision tree model incorporating published data and expert opinion on clinical parameters, resource use and costs (in 2012 US dollars), such as efficacy, mortality, serious adverse events, treatment duration and length of hospital stay. The results presented are from a US payer perspective. The base case first-line treatment duration for patients with MRSA-confirmed nosocomial pneumonia was 10 days. Clinical treatment success (used for the cost-effectiveness ratio) and failure due to lack of efficacy, serious adverse events or mortality were possible clinical outcomes that could impact costs. Cost of treatment and incremental cost-effectiveness per successfully treated patient were calculated for linezolid versus vancomycin. Univariate (one-way) and probabilistic sensitivity analyses were conducted.ResultsThe model allowed us to calculate the total base case inpatient costs as $46,168 (linezolid) and $46,992 (vancomycin). The incremental cost-effectiveness ratio favored linezolid (versus vancomycin), with lower costs ($824 less) and greater efficacy (+2.7% absolute difference in the proportion of patients successfully treated for MRSA nosocomial pneumonia). Approximately 80% of the total treatment costs were attributed to hospital stay (primarily in the intensive care unit). The results of our probabilistic sensitivity analysis indicated that linezolid is the cost-effective alternative under varying willingness to pay thresholds.ConclusionThese model results show that linezolid has a favorable incremental cost-effectiveness ratio compared to vancomycin for MRSA-confirmed nosocomial pneumonia, largely attributable to the higher clinical trial response rate of patients treated with linezolid. The higher drug acquisition cost of linezolid was offset by lower treatment failure–related costs and fewer days of hospitalization.
21 schema:genre article
22 schema:isAccessibleForFree true
23 schema:isPartOf N8748ac8c2c564ccda40523bcabebbace
24 Nb950bea8bd16423191eab18a6616ff87
25 sg:journal.1117766
26 schema:keywords IntroductionWe
27 MRSA
28 MethodsWe
29 ResultsThe model
30 Staphylococcus aureus
31 US payer perspective
32 acquisition costs
33 adverse events
34 alternative
35 analysis
36 aureus
37 clinical outcomes
38 clinical parameters
39 clinical treatment success
40 cost
41 cost of treatment
42 cost-effective alternative
43 cost-effectiveness ratio
44 data
45 days
46 days of hospitalization
47 decision tree model
48 drug acquisition costs
49 duration
50 economic impact
51 efficacy
52 events
53 expert opinion
54 failure
55 favourable incremental cost-effectiveness ratio
56 greater efficacy
57 higher drug acquisition costs
58 hospital stay
59 hospitalization
60 impact
61 incremental cost-effectiveness ratio
62 inpatient costs
63 lack
64 lack of efficacy
65 length
66 linezolid
67 low cost
68 methicillin-resistant Staphylococcus aureus
69 model
70 model results
71 mortality
72 nosocomial pneumonia
73 opinion
74 outcomes
75 parameters
76 patients
77 payer perspective
78 perspective
79 pneumonia
80 possible clinical outcomes
81 probabilistic sensitivity analyses
82 rate
83 ratio
84 resource use
85 response rate
86 results
87 sensitivity analysis
88 serious adverse events
89 stay
90 success
91 threshold
92 total treatment costs
93 treatment
94 treatment costs
95 treatment duration
96 treatment success
97 tree model
98 trial response rates
99 univariate
100 use
101 vancomycin
102 willingness
103 schema:name Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus
104 schema:pagination r157
105 schema:productId N3918f866a43e4afcbf3490e02e524e27
106 N595c14cfeda7486fa8eedc82f379cd2b
107 Nf52ad724a12d49bd809d1d73fc2974d2
108 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039630305
109 https://doi.org/10.1186/cc13996
110 schema:sdDatePublished 2022-09-02T15:57
111 schema:sdLicense https://scigraph.springernature.com/explorer/license/
112 schema:sdPublisher N83a63151f9b841db9850f4efb6731dba
113 schema:url https://doi.org/10.1186/cc13996
114 sgo:license sg:explorer/license/
115 sgo:sdDataset articles
116 rdf:type schema:ScholarlyArticle
117 N0185df00c2334a0688763a122299db4b rdf:first sg:person.015004431252.31
118 rdf:rest N9437f383fb3d47ad87c559e663cb3c5c
119 N0f1e1e1459c74b549414e0883fef3810 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Linezolid
121 rdf:type schema:DefinedTerm
122 N1909b9317ede46c388c4868e7a9ccfb8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Acetamides
124 rdf:type schema:DefinedTerm
125 N1ddd912a95af4825b0a2ae5152578366 rdf:first sg:person.01103526344.19
126 rdf:rest Nede02736a22346e5bb809e2589afe7e3
127 N23bf28b77f5e4c6eabca42d37d48224a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Cross Infection
129 rdf:type schema:DefinedTerm
130 N23c5d2311cf9422db8bb12ccc17efc17 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Humans
132 rdf:type schema:DefinedTerm
133 N2bf221c08e244e9e935e76f74141840d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Methicillin-Resistant Staphylococcus aureus
135 rdf:type schema:DefinedTerm
136 N3918f866a43e4afcbf3490e02e524e27 schema:name dimensions_id
137 schema:value pub.1039630305
138 rdf:type schema:PropertyValue
139 N3d280c777d4744baa2feacccaa98a6ea rdf:first sg:person.0664111222.25
140 rdf:rest N0185df00c2334a0688763a122299db4b
141 N48874feec3dc439081ed94bc6079a05a rdf:first sg:person.01365552716.46
142 rdf:rest Ne4739531b41640e4aab43281d6163d95
143 N4d66558544f344d9b1da3de3d226d2b1 rdf:first sg:person.0714077601.27
144 rdf:rest Ndc853a8287a642b19cf71fe48957f080
145 N4d87ec0f960441deb0d631ed3741515f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Pneumonia, Staphylococcal
147 rdf:type schema:DefinedTerm
148 N595c14cfeda7486fa8eedc82f379cd2b schema:name pubmed_id
149 schema:value 25053453
150 rdf:type schema:PropertyValue
151 N5fefa93e614943ab980e106676243e78 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Models, Economic
153 rdf:type schema:DefinedTerm
154 N83a63151f9b841db9850f4efb6731dba schema:name Springer Nature - SN SciGraph project
155 rdf:type schema:Organization
156 N8748ac8c2c564ccda40523bcabebbace schema:volumeNumber 18
157 rdf:type schema:PublicationVolume
158 N934ea1cd959e4a40a05775c60179f4bd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Anti-Bacterial Agents
160 rdf:type schema:DefinedTerm
161 N9437f383fb3d47ad87c559e663cb3c5c rdf:first sg:person.01340540240.18
162 rdf:rest N1ddd912a95af4825b0a2ae5152578366
163 N9b6bc379ab8b4d8eb6e5890d286a438a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Prospective Studies
165 rdf:type schema:DefinedTerm
166 N9e708ebc23fd4c86a5ad49098d958412 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Oxazolidinones
168 rdf:type schema:DefinedTerm
169 Na7b09744ce5d4a709fee06e9967d9d01 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Vancomycin
171 rdf:type schema:DefinedTerm
172 Nb950bea8bd16423191eab18a6616ff87 schema:issueNumber 4
173 rdf:type schema:PublicationIssue
174 Ndc853a8287a642b19cf71fe48957f080 rdf:first sg:person.01305416464.55
175 rdf:rest N3d280c777d4744baa2feacccaa98a6ea
176 Ndcb717e2bca3467ab8d49e31ae0179ac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Cost-Benefit Analysis
178 rdf:type schema:DefinedTerm
179 Ne4739531b41640e4aab43281d6163d95 rdf:first sg:person.0606505446.70
180 rdf:rest N4d66558544f344d9b1da3de3d226d2b1
181 Nede02736a22346e5bb809e2589afe7e3 rdf:first sg:person.01104424502.36
182 rdf:rest rdf:nil
183 Nf52ad724a12d49bd809d1d73fc2974d2 schema:name doi
184 schema:value 10.1186/cc13996
185 rdf:type schema:PropertyValue
186 Nff1d084527a64747bb8b05e7e32ee5ac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Double-Blind Method
188 rdf:type schema:DefinedTerm
189 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
190 schema:name Medical and Health Sciences
191 rdf:type schema:DefinedTerm
192 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
193 schema:name Clinical Sciences
194 rdf:type schema:DefinedTerm
195 sg:journal.1117766 schema:issn 1364-8535
196 1466-609X
197 schema:name Critical Care
198 schema:publisher Springer Nature
199 rdf:type schema:Periodical
200 sg:person.01103526344.19 schema:affiliation grid-institutes:grid.482835.0
201 schema:familyName Gao
202 schema:givenName Xin
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01103526344.19
204 rdf:type schema:Person
205 sg:person.01104424502.36 schema:affiliation grid-institutes:grid.416266.1
206 schema:familyName Nathwani
207 schema:givenName Dilip
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01104424502.36
209 rdf:type schema:Person
210 sg:person.01305416464.55 schema:affiliation grid-institutes:grid.281603.e
211 schema:familyName Niederman
212 schema:givenName Michael
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01305416464.55
214 rdf:type schema:Person
215 sg:person.01340540240.18 schema:affiliation grid-institutes:None
216 schema:familyName Charbonneau
217 schema:givenName Claudie
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340540240.18
219 rdf:type schema:Person
220 sg:person.01365552716.46 schema:affiliation grid-institutes:grid.482835.0
221 schema:familyName Patel
222 schema:givenName Dipen A
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01365552716.46
224 rdf:type schema:Person
225 sg:person.015004431252.31 schema:affiliation grid-institutes:grid.482835.0
226 schema:familyName Stephens
227 schema:givenName Jennifer M
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015004431252.31
229 rdf:type schema:Person
230 sg:person.0606505446.70 schema:affiliation grid-institutes:grid.415235.4
231 schema:familyName Shorr
232 schema:givenName Andrew F
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0606505446.70
234 rdf:type schema:Person
235 sg:person.0664111222.25 schema:affiliation grid-institutes:grid.413104.3
236 schema:familyName Simor
237 schema:givenName Andrew
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0664111222.25
239 rdf:type schema:Person
240 sg:person.0714077601.27 schema:affiliation grid-institutes:None
241 schema:familyName Chastre
242 schema:givenName Jean
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0714077601.27
244 rdf:type schema:Person
245 sg:pub.10.1007/s15010-008-8046-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012222331
246 https://doi.org/10.1007/s15010-008-8046-7
247 rdf:type schema:CreativeWork
248 grid-institutes:None schema:alternateName Outcomes Research-Europe Infectious Diseases, Pfizer International Operations Specialty, Business Unit 23-25, avenue du Dr Lannelongue, F-75668, Paris Cedex 14, France
249 Service de Réanimation Médicale Institut de Cardiologie Groupe, Hospitalier Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75651, Paris Cedex 13, France
250 schema:name Outcomes Research-Europe Infectious Diseases, Pfizer International Operations Specialty, Business Unit 23-25, avenue du Dr Lannelongue, F-75668, Paris Cedex 14, France
251 Service de Réanimation Médicale Institut de Cardiologie Groupe, Hospitalier Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75651, Paris Cedex 13, France
252 rdf:type schema:Organization
253 grid-institutes:grid.281603.e schema:alternateName Department of Medicine, Winthrop-University Hospital, 222 Station Plaza N, Suite 509, 11501, Mineola, NY, USA
254 schema:name Department of Medicine, Winthrop-University Hospital, 222 Station Plaza N, Suite 509, 11501, Mineola, NY, USA
255 rdf:type schema:Organization
256 grid-institutes:grid.413104.3 schema:alternateName Department of Microbiology, Sunnybrook Health Sciences Centre, B121-2075 Bayview Ave., M4N 3M5, Toronto, ON, Canada
257 schema:name Department of Microbiology, Sunnybrook Health Sciences Centre, B121-2075 Bayview Ave., M4N 3M5, Toronto, ON, Canada
258 rdf:type schema:Organization
259 grid-institutes:grid.415235.4 schema:alternateName Department of Pulmonary & Critical Care Medicine, Washington Hospital Center, 110 Irving St NW, 20010, Washington, DC, USA
260 schema:name Department of Pulmonary & Critical Care Medicine, Washington Hospital Center, 110 Irving St NW, 20010, Washington, DC, USA
261 rdf:type schema:Organization
262 grid-institutes:grid.416266.1 schema:alternateName Ninewells Hospital & Medical School, Ward 42, East Block, DD19SY, Dundee, UK
263 schema:name Ninewells Hospital & Medical School, Ward 42, East Block, DD19SY, Dundee, UK
264 rdf:type schema:Organization
265 grid-institutes:grid.482835.0 schema:alternateName Pharmerit International, 4350 East West Highway, Suite 430, 20814, Bethesda, MD, USA
266 schema:name Pharmerit International, 4350 East West Highway, Suite 430, 20814, Bethesda, MD, USA
267 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...